A lack of understanding about the disease’s physiology makes creating new medicines difficult. “So we hope to revolutionize the way schizophrenics are being treated. … We hope to give these people their lives back,” Remy Luthringer, CEO of Boston-based Minerva Neurosciences, tells Stat. In other biotech and pharmaceutical news: companies thrive in Minnesota. And production resumes at a troubled Pfizer plant.